Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery.
Albumin is a versatile drug carrier in anti-cancer drug delivery system and it also has an actively targeting capacity to tumors. Recently, nanoparticle albumin-bound (nab) paclitaxel (nab-paclitaxel; Abraxane) has been approved in 2006 for use in patients with metastatic breast cancer who have failed in the combination chemotherapy, and so the nab-technology has attracted much interest in the anti-cancer drug delivery system. The details about the preparation, characterization and evaluation of nab-paclitaxel (ABI-007) are discussed. The pharmacokinetics, pharmacodynamics and the clinical trials of ABI-007 are also reviewed. Furthermore, the recent applications of nab-technology in the anti-cancer drug delivery systems are summarized by virtue of the patents pertaining to nab-technology. To sum up, nab-technology has a great potential of being applied extensively in the field of anti-cancer agents delivery in the future in order to acquire the good safety and better therapeutical effect.
Fu
Qiang
Q
Department of Biopharmaceutics, School of Pharmacy, No. 103 of Wenhua Road, Shenyang 110016, PR China.
Sun
Jin
J
Zhang
Wenping
W
Sui
Xiaofan
X
Yan
Zhongtian
Z
He
Zhonggui
Z
D000068196:Albumin-Bound Paclitaxel; D000418:Albumins / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics
D000068196:Albumin-Bound Paclitaxel; D000418:Albumins; D017239:Paclitaxel